N-[(3S,4R)-4-[(dimethylamino)methyl]-1-(pyridin-2-ylmethyl)pyrrolidin-3-yl]-2-(2-methylimidazol-1-yl)acetamide
C19H28N6O — CID 91923193
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[(3S,4R)-4-[(dimethylamino)methyl]-1-(pyridin-2-ylmethyl)pyrrolidin-3-yl]-2-(2-methylimidazol-1-yl)acetamide
N-[(3S,4R)-4-[(dimethylamino)methyl]-1-(pyridin-2-ylmethyl)pyrrolidin-3-yl]-2-(2-methylimidazol-1-yl)acetamide (PubChem CID 91923193) has the molecular formula C19H28N6O and a molecular weight of 356.47 g/mol. Its IUPAC name is N-[(3S,4R)-4-[(dimethylamino)methyl]-1-(pyridin-2-ylmethyl)pyrrolidin-3-yl]-2-(2-methylimidazol-1-yl)acetamide.
Molecular Properties
| Compound Name | N-[(3S,4R)-4-[(dimethylamino)methyl]-1-(pyridin-2-ylmethyl)pyrrolidin-3-yl]-2-(2-methylimidazol-1-yl)acetamide |
|---|---|
| PubChem CID | 91923193 |
| Molecular Formula | C19H28N6O |
| Molecular Weight | 356.47 g/mol |
| Exact Mass | 356.23 |
| IUPAC Name | N-[(3S,4R)-4-[(dimethylamino)methyl]-1-(pyridin-2-ylmethyl)pyrrolidin-3-yl]-2-(2-methylimidazol-1-yl)acetamide |
| SMILES | Cc1nccn1CC(=O)N[C@@H]1CN(Cc2ccccn2)C[C@H]1CN(C)C |
| InChI | InChI=1S/C19H28N6O/c1-15-20-8-9-25(15)14-19(26)22-18-13-24(11-16(18)10-23(2)3)12-17-6-4-5-7-21-17/h4-9,16,18H,10-14H2,1-3H3,(H,22,26)/t16-,18-/m1/s1 |
| InChIKey | AWSATDWGCMCJJP-SJLPKXTDSA-N |
| XLogP | 0.76 |
| TPSA | 66.29 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 26 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 356.47 |
| LogP ≤ 5 | 0.76 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 91923193 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.